Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines
Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.